JGGDR
JGP Global Gestao de Recursos Portfolio holdings
AUM
$204M
This Quarter Return
+4.9%
1 Year Return
+109.69%
3 Year Return
+285.93%
5 Year Return
+345.7%
10 Year Return
+378.07%
AUM
$282M
AUM Growth
+$282M
(+57%)
Cap. Flow
+$103M
Cap. Flow
% of AUM
36.36%
Top 10 Holdings %
Top 10 Hldgs %
84.41%
Holding
81
New
17
Increased
41
Reduced
2
Closed
16
Top Buys
| 1 |
VanEck Gold Miners ETF
GDX
|
$43.9M |
| 2 |
iShares MSCI Emerging Markets ETF
EEM
|
$32.3M |
| 3 |
XP
XP
|
$22.8M |
| 4 |
Energy Select Sector SPDR Fund
XLE
|
$21M |
| 5 |
ARCE
Arco Platform Limited Class A Common Shares
ARCE
|
$17.2M |
Top Sells
| 1 |
Wells Fargo
WFC
|
$20.2M |
| 2 |
AVP
Avon Products, Inc.
AVP
|
$17.1M |
| 3 |
StoneCo
STNE
|
$16.2M |
| 4 |
Mercado Libre
MELI
|
$2.13M |
| 5 |
MSCI
MSCI
|
$1.42M |
Sector Composition
| 1 | Consumer Discretionary | 24.12% |
| 2 | Consumer Staples | 10.76% |
| 3 | Healthcare | 9.06% |
| 4 | Technology | 8.82% |
| 5 | Financials | 8.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
PARA
26
DELISTED
Paramount Global Class B
PARA
| $947K | 0.34% |
+22,565
| New | +$947K |
|
27
Acadia Pharmaceuticals
ACAD
$4.38B
| $940K | 0.33% |
21,963
+167
| +0.8% | +$7.15K |
|
|
ONC
28
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $937K | 0.33% |
5,653
+68
| +1% | +$11.3K |
|
|
ALXN
29
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $816K | 0.29% |
7,549
+84
| +1% | +$9.08K |
|
30
Elevance Health
ELV
$71.8B
| $748K | 0.27% |
2,476
+30
| +1% | +$9.06K |
|
31
Stryker
SYK
$150B
| $734K | 0.26% |
3,495
+42
| +1% | +$8.82K |
|
32
Mondelez International
MDLZ
$79.5B
| $729K | 0.26% |
13,243
+2,595
| +24% | +$143K |
|
33
Cigna
CI
$80.3B
| $682K | 0.24% |
3,334
+40
| +1% | +$8.18K |
|
34
Pfizer
PFE
$141B
| $636K | 0.23% |
16,226
+196
| +1% | +$7.68K |
|
35
Agilent Technologies
A
$35.7B
| $590K | 0.21% |
6,921
+83
| +1% | +$7.08K |
|
36
Danaher
DHR
$147B
| $578K | 0.21% |
3,763
+45
| +1% | +$6.91K |
|
|
AMRN
37
Amarin Corp
AMRN
$311M
| $541K | 0.19% |
25,210
+295
| +1% | +$6.33K |
|
38
Eli Lilly
LLY
$657B
| $537K | 0.19% |
4,085
+49
| +1% | +$6.44K |
|
39
HCA Healthcare
HCA
$94.5B
| $507K | 0.18% |
3,428
+41
| +1% | +$6.06K |
|
40
Ascendis Pharma
ASND
$11.8B
| $474K | 0.17% |
3,405
+45
| +1% | +$6.26K |
|
41
BioMarin Pharmaceuticals
BMRN
$11.2B
| $468K | 0.17% |
5,538
+60
| +1% | +$5.07K |
|
42
Humana
HUM
$36.5B
| $423K | 0.15% |
1,155
+14
| +1% | +$5.13K |
|
43
Bristol-Myers Squibb
BMY
$96B
| $421K | 0.15% |
+6,560
| New | +$421K |
|
44
Centene
CNC
$14.3B
| $405K | 0.14% |
6,445
+78
| +1% | +$4.9K |
|
45
Regeneron Pharmaceuticals
REGN
$61.5B
| $385K | 0.14% |
1,025
+12
| +1% | +$4.51K |
|
46
AstraZeneca
AZN
$248B
| $383K | 0.14% |
7,678
+93
| +1% | +$4.64K |
|
47
Merck
MRK
$210B
| $382K | 0.14% |
4,199
+51
| +1% | +$4.64K |
|
48
Exact Sciences
EXAS
$8.98B
| $341K | 0.12% |
+3,692
| New | +$341K |
|
49
Neurocrine Biosciences
NBIX
$13.8B
| $337K | 0.12% |
3,134
+37
| +1% | +$3.98K |
|
50
Hologic
HOLX
$14.9B
| $320K | 0.11% |
6,133
+74
| +1% | +$3.86K |
|